Floatz logo

ASCRINVACUMAB

HCC

Suzhou Kintor Pharmaceutical Inc,monoclonal_antibodyPhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the HCC cohort.

Asset / SponsorPhaseRating
CARVEDILOL
Tongji Hospital
Phase 4BB
EOB-DTPA
Charite University, Berlin, Germany
Phase 4BB
Hepcortespenlisimut-L
Immunitor LLC
Phase 3B
Tirelizumab
Chen Xiaoping
Phase 4B
DALPICICLIB ISETIONATE
Sun Yat-sen University
Phase 2B

View all 39 →

Same molecule, other indications

ASCRINVACUMAB is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →
substance dependenceDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →